Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALA NASDAQ:KIN NASDAQ:MNKD NASDAQ:OPTN NASDAQ:REPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00▼$0.01N/A-38,715 shs50 shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsMNKDMannKind$5.47+2.2%$4.97$3.38▼$7.63$1.68B1.084.59 million shs5.61 million shsOPTNOptiNose$9.60$9.57$4.82▼$17.18$97.22M-0.8863,682 shsN/AREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-50.00%0.00%0.00%-90.00%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%MNKDMannKind0.00%+12.16%-2.50%+45.48%-18.72%OPTNOptiNose0.00%0.00%0.00%0.00%-15.28%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00$0.00▼$0.01N/A-38,715 shs50 shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsMNKDMannKind$5.47+2.2%$4.97$3.38▼$7.63$1.68B1.084.59 million shs5.61 million shsOPTNOptiNose$9.60$9.57$4.82▼$17.18$97.22M-0.8863,682 shsN/AREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-50.00%0.00%0.00%-90.00%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%MNKDMannKind0.00%+12.16%-2.50%+45.48%-18.72%OPTNOptiNose0.00%0.00%0.00%0.00%-15.28%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/AKINKindred Biosciences 0.00N/AN/AN/AMNKDMannKind 2.89Moderate Buy$10.8698.49% UpsideOPTNOptiNose 2.00Hold$9.00-6.25% DownsideREPHRecro Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KIN, OPTN, REPH, MNKD, and CALA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.0010/10/2025MNKDMannKindLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.0010/8/2025MNKDMannKindWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/6/2025MNKDMannKindZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/27/2025MNKDMannKindWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/18/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.009/5/2025MNKDMannKindOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.009/3/2025MNKDMannKindWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$9.00 ➝ $10.009/2/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.008/26/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.00(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/AKINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29MNKDMannKind$301.74M5.56$0.14 per share39.41($0.29) per share-18.86OPTNOptiNose$81.86M1.19N/AN/A($11.56) per share-0.83REPHRecro Pharma$75.36M0.00N/AN/A$0.90 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00N/AN/AN/AN/AN/AN/AKINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/AMNKDMannKind$27.59M$0.1149.7323.78N/A10.87%-32.60%7.81%11/6/2025 (Estimated)OPTNOptiNose-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%N/AREPHRecro Pharma-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/ALatest KIN, OPTN, REPH, MNKD, and CALA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025MNKDMannKind$0.01N/AN/AN/A$80.47 millionN/A8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/AKINKindred Biosciences0.197.027.02MNKDMannKindN/A2.502.24OPTNOptiNoseN/A0.790.72REPHRecro Pharma2.273.242.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/AKINKindred Biosciences66.89%MNKDMannKind49.55%OPTNOptiNose85.60%REPHRecro Pharma62.34%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%KINKindred Biosciences13.69%MNKDMannKind2.70%OPTNOptiNose2.30%REPHRecro Pharma14.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableKINKindred Biosciences6345.46 millionN/AOptionableMNKDMannKind400306.83 million298.54 millionOptionableOPTNOptiNose19010.13 million9.83 millionNot OptionableREPHRecro Pharma18556.42 million48.41 millionOptionableKIN, OPTN, REPH, MNKD, and CALA HeadlinesRecent News About These CompaniesPharma’s climate change vulnerability and opportunityJuly 19, 2024 | pharmaphorum.comPDorf Ketal's Indian unit acquires veterinary pharma brandApril 10, 2024 | vccircle.comVFuji Pharma Co. Ltd.January 30, 2024 | wsj.comAurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 croreNovember 22, 2023 | moneycontrol.comRetaining the human element of AI within pharma and healthcareNovember 21, 2023 | pharmaphorum.comPHere's what Wall Street expects from Recro Pharma's earnings reportNovember 7, 2023 | markets.businessinsider.comUS supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitsAugust 16, 2023 | theguardian.comMankind Pharma share priceAugust 9, 2023 | livemint.comWhat Wall Street expects from Recro Pharma's earningsAugust 9, 2023 | markets.businessinsider.comMankind Pharma Ltd (MNKI)August 3, 2023 | investing.comEversana and Amazon plan generative AI push in pharmaJuly 30, 2023 | pharmaphorum.comPAurobindo Pharma Ltd.July 24, 2023 | ndtv.comNBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsJune 30, 2023 | bizjournals.comPharma reform: Patients can’t afford to wait. Act now.June 13, 2023 | politico.euPSun Pharma reports "information security incident"; isolates impacted IT assetsMarch 9, 2023 | health.economictimes.indiatimes.comWatch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNLMarch 1, 2023 | ijr.comIAurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividendFebruary 17, 2023 | moneycontrol.comPaytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focusDecember 20, 2022 | financialexpress.comFPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLJune 24, 2022 | benzinga.comSocietal CDMO IncApril 20, 2022 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 AI Stocks With Record Breaking Rallies: Can They Continue?By Dan Schmidt | September 29, 2025Airlines Are Taking Off, With More Gains Left to Price InBy Gabriel Osorio-Mazilli | September 25, 2025AutoZone Pulls Into a Buy-the-Dip OpportunityBy Thomas Hughes | September 24, 2025Why Amazon’s Prime Day May Be the Catalyst for a Year-End RallyBy Sam Quirke | October 9, 2025Cybersecurity Market Set to Double: This ETF Offers ExposureBy Jordan Chussler | September 24, 2025KIN, OPTN, REPH, MNKD, and CALA Company DescriptionsCalithera Biosciences NASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Kindred Biosciences NASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.MannKind NASDAQ:MNKD$5.47 +0.12 (+2.24%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$5.46 -0.01 (-0.18%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.OptiNose NASDAQ:OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Recro Pharma NASDAQ:REPHRecro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
